Drug-drug interaction between voriconazole and oral hypoglycemic agents in diabetic rats

被引:0
|
作者
Kumar, Boyina Hemanth [1 ]
Joshi, Bheemachari [2 ]
Singh, Jayasingh Chellammal Hanish [3 ]
Diwan, Prakash V. [1 ]
机构
[1] Anurag Grp Inst, Sch Pharm, Dept Pharmacol, Hyderabad, Andhra Pradesh, India
[2] NET Pharm Coll, Dept Pharmacol, Raichur, Karnataka, India
[3] KPJ Healthcare Univ Coll, Sch Pharm, Dept Pharmacol, Nilai, Negeri Sembilan, Malaysia
关键词
Drug-drug interaction; glibenclamide; hypoglycemic; pioglitazone; voriconazole; PIOGLITAZONE; PHARMACOKINETICS; IDENTIFICATION; BLOOD;
D O I
10.4103/0253-7613.108299
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The objective was to study the of drug-drug interaction between voriconazole and oral hypoglycemic agents in normal and alloxan induced diabetic rats. Materials and Methods: The study was designed in two phases. In the first phase, influence of glibenclamide (0.45 mg/kg, p.o.) and pioglitazone (2.7 mg/kg, p.o. once daily) on blood glucose levels in normoglycemic rats was studied and then influence of voriconazole (18 mg/kg, p.o. twice daily.) pre-treatment on the hypoglycemic activity studied. Simultaneously the influence of voriconazole treatment for seven consecutive days (per se effect) on blood glucose levels was also studied in normoglycemic rats. In the second phase of the study alloxan-induced diabetic rats were used to find out the influence of voriconazole pre-treatment on glibenclamide and pioglitazone induced hypoglycemic effect in pathophysiological condition. Blood samples were collected from retro orbital plexus at regular intervals of 0.0, 0.5, 1.0, 2.0, 4.0, 8.0, 12.0, 18.0 and 24.0 h after drug treatment. All the blood samples were analyzed for plasma glucose by glucose oxidase peroxidase method (GOD/POD). Results: The therapeutic dose of voriconazole potentiates the hypoglycemic activity of glibenclamide and pioglitazone both in normoglycemic and diabetic rats respectively. Conclusion: The results indicate that the dose of oral hypoglycemic agents needs to be adjusted if co-administered with voriconazole.
引用
收藏
页码:155 / 158
页数:4
相关论文
共 50 条
  • [31] Severe phototoxicity associated with concomitant use of methotrexate and voriconazole, an overlooked drug-drug interaction
    Bogaert, Delfien J.
    Verlinden, Louisa
    Vandecruys, Els
    Laureys, Genevieve
    Verhaeghe, Evelien
    Bauters, Tiene
    PEDIATRIC BLOOD & CANCER, 2020, 67 (06)
  • [33] FURTHER EXPLORATION INTO THE DRUG-DRUG INTERACTION BETWEEN GEMFIBROZIL AND REPAGLINIDE IN RATS: UPTAKE TRANSPORT
    Mccoy, Chase I.
    Stanley, Forrest A.
    Kollu, Chandra
    Muranjan, Seema
    Green, Krystal M.
    Barbara, Joanna E.
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S49 - S50
  • [34] DRUG-DRUG INTERACTION BETWEEN PACHYMIC ACID AND REPAGLINIDE IN RATS AND ITS POTENTIAL MECHANISM
    Gu, Jing
    Zhang, Hui
    Li, Xinxin
    ACTA POLONIAE PHARMACEUTICA, 2024, 81 (02): : 345 - 352
  • [35] Evaluation of drug-drug interaction between rosuvastatin and tacrolimus and the risk of hepatic injury in rats
    Huang, Lulu
    Ning, Chen
    He, Jiake
    Wang, Mingcheng
    Chen, Xijing
    Guo, Xiaohui
    Zhong, Lin
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [36] ORAL HYPOGLYCEMIC AGENTS - REPORT OF FOOD AND DRUG ADMINISTRATION
    EDWARDS, CC
    DIABETES, 1970, 19 : R8 - &
  • [38] Significant drug-drug interaction between warfarin and nafcillin
    King, Cynthia A.
    Babcock, Kathleen M.
    Godios, Rhianna J.
    King, Benjamin S.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2018, 9 (11) : 667 - 671
  • [39] Is There a Drug-Drug Interaction Between Darunavir/Ritonavir and Raltegravir?
    Fabbiani, Massimiliano
    Navarra, Pierluigi
    Cauda, Roberto
    De Luca, Andrea
    Di Giambenedetto, Simona
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 60 (01) : E18 - E20
  • [40] Lack of drug-drug interaction between cerivastatin and nifedipine
    Sachse, R
    Brendel, E
    Muck, W
    Rohde, G
    Ochmann, K
    Horstmann, R
    Kuhlmann, J
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1998, 36 (08) : 409 - 413